Contineum's Non-Opioid Pain Drug Shows Promise in Early Trial

SAN DIEGO, CA – April 30, 2026 – In the global search for effective and safe alternatives to opioids, San Diego-based Contineum Therapeutics today announced a significant step forward. The clinical-stage biopharmaceutical company reported positive topline data from an exploratory Phase 1b trial of its novel drug, PIPE-791, for the treatment of chronic pain, a condition that affects more than one in five adults in the United States alone.

The drug, a once-daily oral pill, showed encouraging signs of efficacy and a strong safety profile in patients suffering from chronic osteoarthritis pain (COAP) and chronic low back pain (CLBP). These early results position PIPE-791 as a promising non-opioid candidate in a market desperate for innovation, potentially offering relief to millions without the risks of addiction and dependency that have fueled a public health crisis.

A Signal of Relief

The primary goal of the Phase 1b study was to assess the safety of PIPE-791, and on that front, it succeeded. The randomized, double-blind, placebo-controlled trial enrolled 43 patients who received a 10mg daily dose over a four-week period. The company reported that the drug was well-tolerated, with most side effects being mild to moderate. The most common adverse events were headache and fatigue, with no serious issues reported. Crucially, the trial observed no clinically meaningful changes in blood pressure, a key safety consideration for any new therapeutic.

“These results demonstrate that PIPE-791, administered as a once-daily 10mg oral dose, was well tolerated in the largest patient population and longest treatment duration studied to date, reinforcing our confidence in its profile,” said Dr. Timothy Watkins, Chief Medical Officer at Contineum Therapeutics, in a statement.

While the study was primarily designed to test safety, the exploratory efficacy data has generated considerable optimism. Using an 11-point scale to rate pain, patients treated with PIPE-791 generally showed numerically greater improvements from their baseline pain levels compared to those on placebo. For instance, in the first treatment period, patients with chronic osteoarthritis pain saw their average pain scores drop by 1.60 points with PIPE-791, compared to a 1.27-point drop with placebo. A similar, more pronounced trend was seen in patients with chronic low back pain, who reported a 1.33-point reduction with the drug versus just 0.55 for placebo.

“We are pleased with these results, which showed consistent trends toward improvement across multiple exploratory efficacy endpoints,” Dr. Watkins added. “We believe these findings, particularly the COAP data, provide evidence of preliminary efficacy that support further evaluation of PIPE-791 for the potential treatment of chronic pain.”

Targeting the Source of Pain

What sets PIPE-791 apart is its novel mechanism of action. The drug is a selective antagonist of the lysophosphatidic acid 1 (LPA1) receptor. Scientific research has increasingly implicated the LPA1 pathway in the generation and maintenance of chronic and neuropathic pain. Its activation can contribute to the demyelination of nerve fibers and neuroinflammation, essentially turning up the volume on pain signals within the central nervous system.

By selectively blocking this receptor, PIPE-791 aims to interrupt these maladaptive processes and treat the underlying cause of pain, rather than just masking the symptoms. This targeted approach is a significant departure from opioids, which act more broadly on the brain's reward systems, and traditional NSAIDs, which primarily address inflammation.

Dr. Robert H. Dworkin, a professor at the University of Rochester Medicine and an expert in the field, commented on the significance of this approach. “Chronic pain remains a very significant unmet medical need, particularly for patients seeking effective and safe non-opioid treatment options,” he noted. “The novel LPA1 activity targets underlying mechanisms of pain. These data provide compelling support for further clinical investigation.”

Navigating a High-Stakes Market

The potential impact of a successful non-opioid pain therapy is immense. The global chronic pain treatment market was valued at approximately $84 billion in 2024 and is projected to soar past $130 billion by the end of the decade, fueled by an aging population and the rising prevalence of chronic diseases. The economic burden is staggering, with chronic pain costing the U.S. economy over $700 billion annually in healthcare expenses and lost productivity.

Contineum Therapeutics (NASDAQ: CTNM) is now positioned as a noteworthy contender in this high-stakes arena. Following the news, investor sentiment remains strong, building on a remarkable year in which the company's stock has seen significant growth. With a reported cash reserve sufficient to fund operations through 2027, Contineum appears well-capitalized to advance its pipeline.

However, the path from a promising early signal to a marketable drug is long and fraught with challenges. The non-opioid pain pipeline is active, with dozens of assets in late-stage clinical development. Contineum will need to replicate and build upon these early findings in much larger, more definitive Phase 2 and Phase 3 trials to prove both statistical and clinical significance to regulators and physicians.

The company has stated it is now “contemplating next steps for further clinical development.” These next trials will be designed to confirm the efficacy signals seen in this exploratory study and to further characterize the safety profile of PIPE-791 in a larger patient population. For the millions living with the daily burden of chronic pain, the progress of PIPE-791 represents a tangible source of hope for a future with better, safer treatment options.